Addressing Challenging Atypical Patients With OAB: Case Discussions (CME/CE Webcast)

Activity Description and Purpose

This webcast, which captures the proceedings of a live CME/CE symposium held during North Central Section AUA 2023, delves into the latest insights and treatment strategies for overactive bladder (OAB). Led by renowned experts in urology, this educational activity covers a spectrum of topics, including diagnostic approaches, behavioral therapies, and pharmacologic treatments. The desired results of this activity are for urologists, urogynecologists, physician assistants, nurse practitioners, and nurses to improve their diagnosis and treatment of OAB. By enhancing their understanding of OAB pathophysiology, diagnostic nuances, and therapeutic options, clinicians will be better prepared to devise personalized treatment plans, improve patient outcomes, enhance quality of care, and address the complex needs of diverse patient populations suffering from OAB.

Target Audience

This educational activity is intended for urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify central nervous system effects of anticholinergic agents used to treat overactive bladder
  • Recount findings of clinical trial data on new treatments for overactive bladder
  • Design appropriate evidence-based treatment strategies for complex patients with overactive bladder
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 


Benjamin M. Brucker, MD (Chair)
Associate Professor
Departments of Urology and Obstetrics and Gynecology
Director, Female Pelvic Medicine and Reconstructive Surgery Program and Neurourology
New York University Langone Health
New York, New York

Aqsa A. Khan, MD
Assistant Professor
Associate Program Director, Urology Residency
Department of Urology
Mayo Clinic
Phoenix, Arizona

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.


Benjamin M. Brucker, MD, is an advisory board member of AbbVie Inc, Palette Life Sciences, Inc, Sumitomo Pharma America, and Watkins-Conti Products; is on the speakers bureau for AbbVie Inc, Solv Wellness, and Sumitomo Pharma America; and is a contracted researcher for AbbVie Inc and Sumitomo Pharma America.

Aqsa A. Khan, MD, has no relevant commercial relationships to disclose.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Satisfactory Completion

Learners must take the pretest, view the webcast, and complete a posttest and evaluation form to receive a certificate of completion. Your session must be viewed in its entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

For Physicians

ACCME Accreditation Statement

 MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

Interprofessional Joint Accreditation Statement

image In support of improving patient care, this activity has been planned and implemented by MedEdicus LLC and Amedco LLC. Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Nursing Credit

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Sumitomo Pharma America.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at

Fee Information

There is no fee for this educational activity.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco LLC, or Sumitomo Pharma America.

This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 300.3

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.